JP2021521227A5 - - Google Patents

Info

Publication number
JP2021521227A5
JP2021521227A5 JP2020556855A JP2020556855A JP2021521227A5 JP 2021521227 A5 JP2021521227 A5 JP 2021521227A5 JP 2020556855 A JP2020556855 A JP 2020556855A JP 2020556855 A JP2020556855 A JP 2020556855A JP 2021521227 A5 JP2021521227 A5 JP 2021521227A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
composition according
compound
Prior art date
Application number
JP2020556855A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521227A (ja
JPWO2019204136A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/027158 external-priority patent/WO2019204136A1/en
Publication of JP2021521227A publication Critical patent/JP2021521227A/ja
Publication of JP2021521227A5 publication Critical patent/JP2021521227A5/ja
Publication of JPWO2019204136A5 publication Critical patent/JPWO2019204136A5/ja
Withdrawn legal-status Critical Current

Links

JP2020556855A 2018-04-16 2019-04-12 神経障害性疼痛を処置する方法 Withdrawn JP2021521227A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862658347P 2018-04-16 2018-04-16
US62/658,347 2018-04-16
PCT/US2019/027158 WO2019204136A1 (en) 2018-04-16 2019-04-12 Methods of treating neuropathic pain

Publications (3)

Publication Number Publication Date
JP2021521227A JP2021521227A (ja) 2021-08-26
JP2021521227A5 true JP2021521227A5 (https=) 2022-04-20
JPWO2019204136A5 JPWO2019204136A5 (https=) 2022-04-20

Family

ID=68239826

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020556855A Withdrawn JP2021521227A (ja) 2018-04-16 2019-04-12 神経障害性疼痛を処置する方法

Country Status (14)

Country Link
US (1) US20210154170A1 (https=)
EP (1) EP3781157A4 (https=)
JP (1) JP2021521227A (https=)
KR (1) KR20210002472A (https=)
CN (1) CN112367990A (https=)
AU (1) AU2019255519A1 (https=)
BR (1) BR112020021101A2 (https=)
CA (1) CA3093401A1 (https=)
EA (1) EA202092482A1 (https=)
IL (1) IL277962A (https=)
MX (1) MX2020010929A (https=)
SG (1) SG11202008681PA (https=)
TW (2) TW202245750A (https=)
WO (1) WO2019204136A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2264182A1 (en) * 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
TW200730494A (en) * 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
GB201409851D0 (en) * 2014-06-03 2014-07-16 Convergence Pharmaceuticals Diagnostic method
GB201417497D0 (en) * 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
JP2019537601A (ja) * 2016-11-02 2019-12-26 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. 新規投薬レジメン

Similar Documents

Publication Publication Date Title
JP2023002662A5 (https=)
JP2021522247A5 (https=)
RU2010140682A (ru) Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство
JP2014515373A5 (https=)
JP2015505564A5 (https=)
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
JP2015510916A5 (https=)
RU2014141893A (ru) Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
EA202190544A1 (ru) Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний
JP2017514911A5 (https=)
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний
JP2008539273A5 (https=)
JPWO2021168403A5 (https=)
JP2016505050A5 (https=)
JP2019507786A5 (https=)
JP2016528171A5 (https=)
JP2021521227A5 (https=)
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
JPWO2019209738A5 (https=)
WO2018163119A1 (en) 1-piperidinepropionic acid for treating a fibrosing disease
TN2016000179A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.